Table 2.
Indicators | MS in 2006–2008 | MS in 2009–2011 | MS in 2012–2014 |
---|---|---|---|
n (%) | n (%) | n (%) | |
BMI | |||
<24 | 942 (11.14) | 1145 (14.13) | 1359 (17.64) |
24–26.9 | 978 (33.53) | 1280 (41.78) | 1483 (45.84) |
≥27 | 976 (67.17) | 1161 (70.02) | 1441 (76.49) |
Waist (cm) | |||
<80(F); <90(M) | 1582 (14.37) | 1989 (18.41) | 2300 (22.08) |
Otherwise | 1314 (72.24) | 1597 (79.06) | 1983 (82.28) |
Fasting glucose (mg/dL) | |||
<100 | 657 (7.69) | 743 (9.68) | 768 (11.34) |
≥100 | 2239 (52.24) | 2843 (55.24) | 3515 (58.10) |
Triglyceride (mg/dL) | |||
<150 | 1475 (13.98) | 1836 (17.73) | 2305 (22.62) |
≥150 | 1421 (62.52) | 1750 (70.91) | 1978 (75.09) |
HDL (mg/dL) | |||
≥40 (M); ≥50(F) | 2367 (22.47) | 3213 (27.85) | 3807 (33.22) |
Otherwise | 529 (23.09) | 373 (28.98) | 476 (34.87) |
LDL (mg/dL) | |||
<130 | 1771 (19.19) | 2372 (24.67) | 2359 (27.98) |
≥130 | 1125 (31.28) | 1214 (37.81) | 1924 (43.79) |
TC (mg/dL) | |||
<200 | 1340 (16.85) | 1650 (21.56) | 1960 (27.15) |
200–239 | 1156 (29.44) | 1463 (35.13) | 1775 (40.10) |
≥240 | 400 (42.24) | 473 (47.02) | 548 (46.44) |
Hypertension | |||
Normal | 1088 (10.59) | 1537 (15.09) | 1911 (19.47) |
High normal | 975 (63.93) | 1109 (72.82) | 1210 (74.46) |
Phase 1 | 679 (80.26) | 779 (83.76) | 940 (82.89) |
Phase 2–3 | 147 (84.48) | 153 (86.44) | 217 (88.21) |
Other | 7 (77.78) | 8 (88.89) | 5 (71.43) |
Medicine | |||
Antihyperglycemic drug | |||
Yes | 188 (100.00) | 282 (100.00) | 372 (100.00) |
No | 2708 (21.43) | 3304 (26.34) | 3911 (31.41) |
Antihyperlipidemic drug | |||
Yes | 184 (100.00) | 300 (100.00) | 410 (100.00) |
No | 2712 (21.45) | 3286 (26.24) | 3873 (31.20) |
Antihypertensive drug | |||
Yes | 733 (100.00) | 995 (100.00) | 1237 (100.00) |
No | 2163 (17.89) | 2591 (21.90) | 3046 (26.29) |
Framingham CVD score | |||
Mean (standard deviation) | 0.014 (0.015) | 0.014 (0.014) | 0.015 (0.016) |
Medium | 0.009 | 0.009 | 0.010 |